Emerging role of liquid biopsy of cell-free tumor DNA for bladder cancer surveillance

Minyong Kang, Ja Hyeon Ku


Urothelial bladder cancer (UBC) is the second most common type of malignancy in the urinary tract with a high frequency of recurrence and a high progression rate (1). Prior to deciding on a therapeutic strategy, appropriate risk assessment and outcome prediction are critical for achieving better prognosis in patients with UBC who required adjuvant treatments (2).